Comparative cost-effectiveness of ivermectin versus topical organophosphate in feedlot yearlings.
A replicated-pen field trial was performed under commercial feedlot conditions in western Canada to determine the cost-effectiveness of administering ivermectin to yearling beef cattle upon entry to the feedlot after the grazing season, and to establish the level of trichostrongylid gastrointestinal parasite infection in this population, as estimated by fecal egg counts. Six thousand eight hundred and eighty-three, mixed breed, yearling steers were randomly allocated upon arrival at the feedlot to one of 2 experimental groups as follows: Ivermectin, which received topical ivermectin (0.5%) at the rate of 1.0 mL/10 kg body weight; or Fenthion, which received topical fenthion (20%) at the rate of 12 mL/295 kg body weight. There were 15 pens in each experimental group. Final weight, weight gain, average daily gain, and dry matter intake to gain ratio were significantly (P < 0.05) improved in the Ivermectin group as compared with the Fenthion group. There were no significant (P > or = 0.05) differences in initial weight, days on feed, or daily dry matter intake between the experimental groups. The geometric mean fecal egg counts at the time of allocation were 14.7 eggs/5 g and 16.6 eggs/5 g for the Ivermectin and Fenthion groups, respectively (P > or = 0.05). There were no significant (P > or = 0.05) differences in morbidity or mortality between the experimental groups. In the economic analysis, the significant improvements in feedlot performance in the Ivermectin group resulted in a net economic advantage of $4.20 CDN per animal.
Schunicht
O C
OC
Feedlot Health Management Services, Okotoks, Alberta.
Guichon
P T
PT
Booker
C W
CW
Jim
G K
GK
Wildman
B K
BK
Ward
T I
TI
Bauck
S W
SW
Gross
S J
SJ
D000003:Abattoirs; D000287:Administration, Topical; D000818:Animals; D000969:Antinematodal Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000469:parasitology*; D003362:Cost-Benefit Analysis; D005284:Fenthion / Q000008:administration & dosage / Q000627:therapeutic use; D007306:Insecticides / Q000008:administration & dosage / Q000627:therapeutic use; D007559:Ivermectin / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D010270:Parasite Egg Count; D014252:Trichostrongyloidiasis / Q000188:drug therapy*
D000969:Antinematodal Agents; D007306:Insecticides; D007559:Ivermectin; D005284:Fenthion